Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets
05:12pm, Tuesday, 24'th Mar 2026
On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes.
ImmunityBio stock price crash: buy the dip or sell the rip?
03:25pm, Tuesday, 24'th Mar 2026
ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a scathing warning letter over the firm's promotional tactics. Investors bai
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
01:46pm, Tuesday, 24'th Mar 2026
IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses
Why ImmunityBio Stock Is Down More Than 20% Today
12:39pm, Tuesday, 24'th Mar 2026
The United States' Food & Drug Administration is being forced to repeatedly address the same issue with ImmunityBio's management. Ironically, the biopharma company's addressable actions don't offer a
ImmunityBio Crashes On FDA Warning Over Anktiva Claims
11:04am, Tuesday, 24'th Mar 2026
ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad
10:53am, Tuesday, 24'th Mar 2026
Shares of ImmunityBio fell 20% on Tuesday after the U.S. Food and Drug Administration issued a warning letter that said a television advertisement and podcast promoting its cancer therapy were �
Why ImmunityBio Stock Is Up More Than 11% Today
03:16pm, Monday, 23'rd Mar 2026
ImmunityBio recently won another approval for its oncology drug Anktiva. Although this approval in and of itself doesn't translate into a massive revenue opportunity, it does set the stage for signifi
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
11:00am, Monday, 23'rd Mar 2026
ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
01:08pm, Friday, 20'th Mar 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People's
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
04:39pm, Tuesday, 17'th Mar 2026
ImmunityBio remains a long-term buy, with Anktiva's regulatory and global expansion driving the investment thesis. IBRX's EU commercial rollout via Accord Healthcare and new Dublin subsidiary rapidly
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use
01:54pm, Tuesday, 17'th Mar 2026
The agency included Anktiva in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
09:45am, Tuesday, 17'th Mar 2026
ImmunityBio IBRX had an encouraging year in 2025. Last month, the company reported its fourth-quarter and full-year 2025 results, which beat both our earnings and sales estimates — all thanks to the
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated it
IBRX Stock Jumps on Progress in NK Cell Therapy Production
02:35pm, Monday, 16'th Mar 2026
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.
